Rp Management 13F annual report
Rp Management is an investment fund managing more than $179 billion ran by Jason Mehar. There are currently 4 companies in Mr. Mehar’s portfolio. The largest investments include Biohaven Ltd and Cytokinetics Inc, together worth $155 billion.
$179 billion Assets Under Management (AUM)
As of 6th August 2024, Rp Management’s top holding is 2,936,507 shares of Biohaven Ltd currently worth over $102 billion and making up 57.0% of the portfolio value.
Relative to the number of outstanding shares of Biohaven Ltd, Rp Management owns more than approximately 0.1% of the company.
In addition, the fund holds 980,392 shares of Cytokinetics Inc worth $53.1 billion, whose value fell 27.1% in the past six months.
The third-largest holding is Biocryst Pharmaceuticals worth $23.8 billion and the next is Viracta Therapeutics Inc worth $2 million, with 3,700 shares owned.
Currently, Rp Management's portfolio is worth at least $179 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Rp Management
The Rp Management office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Jason Mehar serves as the SVP, Investments & Deputy General Counsel at Rp Management.
Recent trades
In the most recent 13F filing, Rp Management revealed that it had opened a new position in Cytokinetics Inc and bought 980,392 shares worth $53.1 billion.
One of the smallest hedge funds
The two most similar investment funds to Rp Management are Council and Ivc Wealth Advisors. They manage $179 billion and $179 billion respectively.
Jason Mehar investment strategy
Rp Management’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 100.0% of
the total portfolio value.
The fund focuses on investments in the United States as
75.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
approximately 0.1% of the total holdings value.
On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $2.24 billion.
The complete list of Rp Management trades based on 13F SEC filings
These positions were updated on August 13th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Biohaven Ltd |
No change
2,936,507
|
$101,926,158,000 | 57.00% |
| Cytokinetics Inc |
Opened
980,392
|
$53,117,639,000 | 29.71% |
| Biocryst Pharmaceuticals Inc. |
No change
3,846,154
|
$23,769,232,000 | 13.29% |
| Viracta Therapeutics Inc |
No change
3,700
|
$1,998,000 | 0.00% |
| No transactions found | |||
| Showing first 500 out of 4 holdings | |||
Hedge funds similar to Rp Management
- Inspire Trust Co, N.a
- Renaissance Capital
- 1623 Capital
- K2 Principal Fund, L.P.
- New England Capital Advisors
- Prostatis
- Ivc Wealth Advisors
- Council
- Cna Financial Corp
- Diametric Capital, L.P.
- Impactfolio
- Omega Fund Management
- Mark Sheptoff Financial Planning
- Lsp Investment Advisors